Skip to content

Using Patient-Centered Guidelines in a Technology Platform to Improve Health Care in Adults With Sickle Cell Disease

Using Patient-Centered Guidelines in a Technology Platform to Improve Health Care in Adults With Sickle Cell Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03629678
Enrollment
67
Registered
2018-08-14
Start date
2018-07-01
Completion date
2023-07-01
Last updated
2025-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sickle Cell Disease

Keywords

mhealth

Brief summary

SCD is an inherited disorder of hemoglobin that affects over 100,000 Americans, most of whom live in low-resourced neighborhoods. Acute SCD complications result in 230,000 emergency department visits and $1.5 billion annually in acute-care expenditures. Prior research indicates that increased disease-specific knowledge correlates with improved clinical outcomes in SCD. Thus, targeting strategies to improve disease-specific knowledge is a high priority in the care of individuals with SCD. Significant evidence describes how educational materials, including online educational programs, can be used to increase disease-specific knowledge. In this study, the investigators will evaluate a mobile phone technology intervention based on the prior evidence that technologies can improve SCD-specific knowledge.

Detailed description

Sickle cell disease (SCD) is an inherited blood disorder that affects over 100,000 Americans, an underserved population with low life expectancy and risk for significant and life-threatening medical complications (e.g., stroke). Adults with SCD are overwhelmingly members of socially disadvantaged groups, increasing their risk for disparities in care. Annual health expenditure for individuals with SCD in the United States is about $1.5 billion, primarily from multiple emergency room visits (230,000 visits/year) for management of acute complications. Use of disease-specific knowledge has emerged as a powerful tool to decrease health care utilization. Significant evidence has described how to increase disease-specific knowledge using educational materials, including online educational programs in individuals managing chronic diseases, including SCD. Patient knowledge and use of disease-specific information like evidence-based clinical guidelines has the potential to decrease health care utilization. In 2014, the National Heart, Lung, and Blood Institute (NHLBI) published guidelines for evidence-based management of SCD for health care providers. However, to date, no national strategy has been developed to make these guidelines patient-centered, accessible, and actionable for adults with SCD. Federal Meaningful Use regulations have recommended using health-related technologies to improve patient access to their health information to promote patient engagement. Yet, many adults with SCD are not yet fully engaged in use of health technologies because they are unsure of the best format (e.g., mobile or web-based), leading to a health care technology gap. Mobile health applications (apps) that include patient-centered care guidelines could engage and activate this population given the high use of mobile technologies, potentially closing this health technology gap and improving health outcomes. Evaluate the feasibility and acceptability of the refined iManage in a pilot study with adults with SCD. The investigators will recruit 50 adults from the population of 250 adults with SCD at the Vanderbilt Meharry Sickle Cell Disease Center of Excellence and the ohio state university comprehensive sickle cell center for a 6-month pilot study to evaluate usability, acceptance, and usage. At the end of the study, the investigators will conduct interviews with a subset of participants to gain an in-depth understanding of usage patterns and how to sustain engagement to promote ongoing app use. Evaluate the efficacy of the refined iManage app on SCD-specific knowledge. The investigators will test the hypothesis that the refined iManage will increase SCD-specific knowledge by measuring SCD-specific knowledge at the start and end of the 6-month pilot study. the investigators will conduct exploratory analyses of secondary outcomes including patient activation, adherence to guidelines, missed days of school/work, and self-efficacy.

Interventions

The user-driven technological tool will include an mHealth mobile phone application. Features of the application will be based on preliminary work from the investigators' sites. The mobile app will include fully searchable provider-facing and patient-facing interfaces with the SCD-specific guidelines. The provider-facing interface, designed to be used by providers, will be separated by patient's age to accommodate pediatric and adult providers. The patient-facing interface will display the guidelines that are age- and health literacy-appropriate. Through the mobile app, the investigators will reinforce important points of guideline content; motivate patient engagement through quizzes and text-message reminders; and facilitate peer support, for instance by forming teams to compete against each other to attain goals.

Sponsors

Ohio State University
CollaboratorOTHER
National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
Vanderbilt University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

Randomized controlled trial

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* receives care at the community health clinic, * diagnosis of SCD (Hgb SS, SC, Sβ-thal), * ability to speak and understand written English * has access to a smartphone or computer * between 18-70 years.

Exclusion criteria

* lack of access to a smartphone or computer * inability to speak and understand written English

Design outcomes

Primary

MeasureTime frameDescription
SCD-specific Knowledge6 monthsKnowledge about SCD. This is a questionnaire that is multiple choice and asks questions about sickle cell disease with one correct answer and 3 incorrect answers. The investigators will sum up the number of correct answers which will be reported. There were a total of 39 questions, so a maximum score of 39. This is not a scale.

Secondary

MeasureTime frameDescription
Self-efficacy6 monthssickle cell self-efficacy scale, as described in Edwards R, Telfair J, Cecil H, Lenoci J. Reliability and validity of a self-efficacy instrument specific to sickle cell disease. Behav Res Ther. 2000;38(9):951-63. Scale is 0-45, higher score is better Scale has no subscales and measures self-efficacy
Healthcare Utilization (ER Visits and Hospitalizations)6 monthsThe investigators will measure a count of the # ER visits and # of hospitalizations (i.e., # ER visits + # hospitalizations)
Usage and Usability of the mHealth Application6 monthsHow often app and functionality was used. Usability will be measured by the widely used and validated System Usability Scale as described in Brooke J. SUS-A quick and dirty usability scale. Usability evaluation in industry. 1996;189(194):4-7. The mobile health application for the guidelines has built-in tracking of the number of times the application is launched, how many times each of the functions are used, and how many times each button has been pushed. To measure usage, the investigators will record the numbers of each of these events for each participant. In addition to total use, the investigators will measure usage over time including any use, initial use, periodic use, and sustained use. SUS scale is 0-100, higher score is better. Scale has no subscales and measures usability of the app
Patient Activation Measure6 monthsThe Patient Activation Measure (PAM) is a 10-item questionnaire to assesses a patient's knowledge, skills, and confidence in managing their health and healthcare. Response options range from (1) disagree strongly to (4) agree strongly, and an additional not applicable option. The sum of responses (excepting non-applicable items) are converted using Insignia Health's proprietary algorithm (that takes into account the specific wording and weighting of each item in the survey) into a final PAM score on a 0-100 scale. Higher PAM scores indicate a greater level of patient activation in managing their health.

Countries

United States

Participant flow

Recruitment details

We conducted a feasibility randomized controlled trial at two centers: Vanderbilt University Medical Center and the Ohio State University, between 2018-2022. The IRBs approved the trial at each institution. Participants were recruited from sickle cell medical clinics.

Participants by arm

ArmCount
Control Group (Booklets)
Group 1 will receive the control arm with a paper booklet of the patient-centered SCD-guidelines with education by a health care provider at a single visit
25
Mobile Health Application
Group 2 will receive continuous access to technology-based patient-centered SCD-specific guidelines using a user-driven technological platform, plus a paper booklet of the guidelines with education by a health care provider at a single visit. The mobile app will include interactive content and a fully searchable collection of the SCD-specific guidelines that are age- and health literacy-appropriate. mobile health application: The user-driven technological tool will include an mHealth mobile phone application. Features of the application will be based on preliminary work from the investigators' sites. The mobile app will include fully searchable provider-facing and patient-facing interfaces with the SCD-specific guidelines. The provider-facing interface, designed to be used by providers, will be separated by patient's age to accommodate pediatric and adult providers. The patient-facing interface will display the guidelines that are age- and health literacy-appropriate. Through the mobile app, the investigators will reinforce important points of guideline content; motivate patient engagement through quizzes and text-message reminders; and facilitate peer support, for instance by forming teams to compete against each other to attain goals.
31
Total56

Baseline characteristics

CharacteristicControl Group (Booklets)Mobile Health ApplicationTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants1 Participants1 Participants
Age, Categorical
Between 18 and 65 years
25 Participants30 Participants55 Participants
Age, Continuous30.8 years
STANDARD_DEVIATION 8.82
35.6 years
STANDARD_DEVIATION 10.9
33.5 years
STANDARD_DEVIATION 10.2
Ethnicity (NIH/OMB)
Hispanic or Latino
24 Participants27 Participants51 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
1 Participants3 Participants4 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants1 Participants1 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
23 Participants31 Participants54 Participants
Race (NIH/OMB)
More than one race
2 Participants0 Participants2 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
0 Participants0 Participants0 Participants
Region of Enrollment
United States
25 participants31 participants56 participants
Sex: Female, Male
Female
9 Participants16 Participants25 Participants
Sex: Female, Male
Male
16 Participants15 Participants31 Participants
Sickle cell genotype
Don't know
1 Participants0 Participants1 Participants
Sickle cell genotype
Hemoglobin SC / Sbeta+ thalassemia
10 Participants12 Participants22 Participants
Sickle cell genotype
Hemoglobin SS / Sbeta0 thalassemia
14 Participants19 Participants33 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 300 / 37
other
Total, other adverse events
0 / 300 / 37
serious
Total, serious adverse events
0 / 300 / 37

Outcome results

Primary

SCD-specific Knowledge

Knowledge about SCD. This is a questionnaire that is multiple choice and asks questions about sickle cell disease with one correct answer and 3 incorrect answers. The investigators will sum up the number of correct answers which will be reported. There were a total of 39 questions, so a maximum score of 39. This is not a scale.

Time frame: 6 months

ArmMeasureGroupValue (MEDIAN)
Control Group (Booklets)SCD-specific KnowledgeBaseline32.0 score on a scale
Control Group (Booklets)SCD-specific Knowledge6-month follow up33.5 score on a scale
Mobile Health ApplicationSCD-specific KnowledgeBaseline32.0 score on a scale
Mobile Health ApplicationSCD-specific Knowledge6-month follow up33 score on a scale
Secondary

Healthcare Utilization (ER Visits and Hospitalizations)

The investigators will measure a count of the # ER visits and # of hospitalizations (i.e., # ER visits + # hospitalizations)

Time frame: 6 months

ArmMeasureValue (MEDIAN)
Control Group (Booklets)Healthcare Utilization (ER Visits and Hospitalizations)0 events
Mobile Health ApplicationHealthcare Utilization (ER Visits and Hospitalizations)0 events
Secondary

Patient Activation Measure

The Patient Activation Measure (PAM) is a 10-item questionnaire to assesses a patient's knowledge, skills, and confidence in managing their health and healthcare. Response options range from (1) disagree strongly to (4) agree strongly, and an additional not applicable option. The sum of responses (excepting non-applicable items) are converted using Insignia Health's proprietary algorithm (that takes into account the specific wording and weighting of each item in the survey) into a final PAM score on a 0-100 scale. Higher PAM scores indicate a greater level of patient activation in managing their health.

Time frame: 6 months

ArmMeasureValue (MEDIAN)
Control Group (Booklets)Patient Activation Measure73.8 score on a scale
Mobile Health ApplicationPatient Activation Measure73.8 score on a scale
Secondary

Self-efficacy

sickle cell self-efficacy scale, as described in Edwards R, Telfair J, Cecil H, Lenoci J. Reliability and validity of a self-efficacy instrument specific to sickle cell disease. Behav Res Ther. 2000;38(9):951-63. Scale is 0-45, higher score is better Scale has no subscales and measures self-efficacy

Time frame: 6 months

ArmMeasureValue (MEDIAN)
Control Group (Booklets)Self-efficacy34.5 score on a scale
Mobile Health ApplicationSelf-efficacy32.5 score on a scale
Secondary

Usage and Usability of the mHealth Application

How often app and functionality was used. Usability will be measured by the widely used and validated System Usability Scale as described in Brooke J. SUS-A quick and dirty usability scale. Usability evaluation in industry. 1996;189(194):4-7. The mobile health application for the guidelines has built-in tracking of the number of times the application is launched, how many times each of the functions are used, and how many times each button has been pushed. To measure usage, the investigators will record the numbers of each of these events for each participant. In addition to total use, the investigators will measure usage over time including any use, initial use, periodic use, and sustained use. SUS scale is 0-100, higher score is better. Scale has no subscales and measures usability of the app

Time frame: 6 months

ArmMeasureValue (MEDIAN)
Control Group (Booklets)Usage and Usability of the mHealth Application56.2 score on a scale

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026